tbuckley/cabot-search huggingface dataset:
Celebrating the ACP Centennial: From the <i>Annals</i> Archive
Authors: Deborah Cotton
Journal: Annals of Internal Medicine (2015)

Editorials17 February 2015Celebrating the ACP Centennial: From the Annals ArchiveDeborah Cotton, MD, MPH, Deputy EditorDeborah Cotton, MD, MPH, Deputy EditorSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M14-2819 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail During the 2015 centennial year of the American College of Physicians, publisher of Annals of Internal Medicine, Annals editors will link an article in each issue with an earlier paper from our archives addressing the same disease or clinical question. We hope our readers find this interesting, and we welcome comments, especially from physicians who were practicing at the time of publication of the original paper who might offer insight into the impact of the earlier paper on their knowledge or practice.In this issue, DeFilippis and colleagues (1) conclude that several cardiovascular risk-scoring systems, including versions of the Framingham ...References1. DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266-75. doi:10.7326/M14-2820 LinkGoogle Scholar2. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease—six-year follow-up experience: The Framingham Study. Ann Intern Med. 1961;55:33-50. doi:10.7326/0003-4819-55-1-33 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFactors of Risk in the Development of Coronary Heart Disease—Six-Year Follow-up Experience WILLIAM B. KANNEL , THOMAS R. DAWBER , ABRAHAM KAGAN , NICHOLAS REVOTSKIE , and JOSEPH STOKES III An Analysis of Calibration and Discrimination Among Multiple Cardiovascular Risk Scores in a Modern Multiethnic Cohort Andrew P. DeFilippis , Rebekah Young , Christopher J. Carrubba , John W. McEvoy , Matthew J. Budoff , Roger S. Blumenthal , Richard A. Kronmal , Robyn L. McClelland , Khurram Nasir , and Michael J. Blaha An Analysis of Calibration and Discrimination Among Multiple Cardiovascular Risk Scores in a Modern Multiethnic Cohort Andrew P. DeFilippis , Rebekah Young , Christopher J. Carrubba , John W. McEvoy , Matthew J. Budoff , Roger S. Blumenthal , Richard A. Kronmal , Robyn L. McClelland , Khurram Nasir , and Michael J. Blaha Metrics 17 February 2015Volume 162, Issue 4Page: 310KeywordsArchivesCoronary heart diseaseElectrocardiographyHypertensionLipoproteinsLongitudinal studiesMyocardial infarctionRisk managementThorax ePublished: 17 February 2015 Issue Published: 17 February 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Legends Transposed
Journal: JAMA (1964)

venously is more than adequate dosage to produce uterine contractions.The intravenous administra¬ tion of these drugs circumvents the problems of absorption associated with intramuscular or sub¬ cutaneous injections.Hazard to an unrecognized twin is prevented by giving the drug following the third stage of labor.From the standpoint of efficacy, oxytocin and methylergonovine maléate differ little in the man¬ agement of the fourth stage of labor.As treatment was unnecessary in 88% of the women receiving the placebo, and atony developed in 5% of those who did receive treatment, the routine use of oxytocie drugs would seem to be of benefit to only 7% of patients postpartum.
Antithrombin III assays
Authors: R. H. Yue
Journal: JAMA (1979)

<h3>To the Editor.—</h3> In a letter to the editor, Roger L. Bick, MD (239:296, 1978), commented on the clinical determination of antithrombin III, pointing out the usefulness of chromogenic substrate and that an increased predisposition to thromboembolic phenomena is associated with a decreased antithrombin III level. In reply, Harry L. Messmore, MD, and Jawed Fareed, PhD (240:345, 1978), questioned the use of autolytic forms of thrombin and the chromogenic substrate in the antithrombin III assay. The methods employed for antithrombin III assay can be roughly classified into two categories: immunological and functional. There are two types of functional assays available: the rate determination procedure and the end-point analysis. The rate of the inhibition of thrombin by antithrombin III depends on (1) the amount of antithrombin III present, (2) the amount of heparin or heparin-like substance present in the sample, and (3) the quantity of thrombin employed. It was first pointed
General Surgery.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Wrong Virus Isolation Medium
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of Dietary Fish and Omega-3 Intake with Plasma Glucose
Authors: Martha L Daviglus, Kiang Liu, David Siscovick, Carlos Iribarren, David Jacobs, Sujata Archer
Journal: Circulation (2001)

P88 OBJECTIVE: Dietary fish and omega-3 fatty acids (n-3 FAs) are associated with a reduced risk of CHD mortality. However, enthusiasm for the intake of fish and n-3 FAs in type 2 diabetics has been tempered by reports of impaired glucose homeostasis. Most studies showing this negative impact of fish intake and n-3 FAs on glycemic control have been feeding or supplement studies conducted for short time periods. There are little data on the relationship of fish and n-3 FA intake to glucose levels in free-living diabetic populations. This study examines the associations of dietary fish and n-3 FAs with blood glucose levels among participants with type 2 diabetes from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. METHODS: A total of 43 diabetic (i.e., fasting glucose levels &gt;125 mg/dl) black and white men and women average age 33.6 years in 1992-1993 were included in analyses. Data on fish and n-3 FAs [α-linolenic acid (ALA, 18:3n-3), eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3)] were obtained from an interviewer administered diet history questionnaire. RESULTS: Average amount of fish consumed was 25.34 oz/mo. Mean intake of ALA, EPA, and DHA was 2.2 g/d, 0.07 g/d, and 0.13 g/d, respectively. Spearman rho correlations show a nonsignificant direct association of glucose with intake of fish (ρ=0.10), ALA (ρ=0.18), EPA (ρ=0.24), and DHA (ρ=0.11). For diabetics who consumed fish (n=29), mean glucose was 196.1 mg/dl compared to 208.9 mg/dl for the nonconsumers (n=14). Average glucose levels were highest for the highest tertile of n-3 FAs, e.g., for DHA intake (from lowest to highest) 191.1 mg/dl, 211.5 mg/dl, and 213.0 mg/dl. However, with adjustment for age, BMI, race, sex, education, alcohol and smoking this pattern changed, mean glucose levels were lowest for highest tertile of DHA intake, i.e, (from lowest to highest) 202.1 mg/dl, 215.9 mg/dl, and 196.3 mg/dl. CONCLUSION: In this cohort of free living young diabetics with typical low to moderate fish consumption, no significant differences in blood glucose levels were observed with intake of fish or n-3 FAs. Fish consumption at moderate levels does not appear to be associated with poor glycemic control.
DRUGGISTS' RESPONSIBILITIES.
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3264: A novel TLR8 agonist induces immune responses and tumor regression
Authors: Yuxun Wang, Heping Yang, Huanping Li, Shuda Zhao, Yin Zhang, Renjie Huang, Jinmiao Wu, Yikun Zeng, Panpan Zhang, Xingzhong Zhang, Longsheng Wang, Guangliang Fu, Zhiheng Wu, Panhu Zhu, Hui Xu, Yaqiao Gao, Pei Wang, Daxin Gao
Journal: Cancer Research (2019)

Abstract Toll like receptors (TLRs) have been a recent focus of drug discovery for cancer immunotherapy. TLRs play a crucial role in bridging innate and adaptive immunity. TLR8 is distinguished from other TLRs by its functions in reversing regulatory T (Treg) cell and myeloid derived suppressor cell (MDSC)’s immune suppression effects. Treg and MDSCs induce an immunosuppressive microenvironment that is a major cause of failed tumor immunotherapy. Therefore, activation of TLR8 can exert potent immune-mediated anticancer activity. We discovered a novel TLR8 selective agonist DN052 and demonstrated that DN052 clearly differentiated from motolimod, the only TLR8 agonist drug candidate in clinical development. DN052 was more potent than motolimod and exhibited better PK profiles and more strongly induced immune responses in the in vivo monkey and ex vivo human PBMC studies. However, it has been challenging to characterize TLR8 agonists in vivo partially due to the phylogenetic specificity of TLR8 and its diminished activity in rodents. We developed two new in vivo approaches using mouse syngeneic and mouse xenograft tumor models. Our in vivo studies showed that DN052 strongly suppressed tumor growth in a dose-dependent manner as a single agent and combination with the chemotherapeutic agent or PD-1 monoclonal antibody further enhanced the efficacy of the single agents in several tumor models. Remarkably, DN052 caused complete tumor regression as a single agent or in combination in some of the immune-competent tumor-bearing mice. GLP toxicity studies in rats and monkeys showed that DN052 had favorable safety profiles. Taken together, DN052 is a novel Best-in-Class TLR8 selective agonist for immunotherapy as a single agent or in combination with other immuno-oncology agents or chemotherapeutics for broad cancer indications. DN052 warrants further clinical development. Citation Format: Yuxun Wang, Heping Yang, Huanping Li, Shuda Zhao, Yin Zhang, Renjie Huang, Jinmiao Wu, Yikun Zeng, Panpan Zhang, Xingzhong Zhang, Longsheng Wang, Guangliang Fu, Zhiheng Wu, Panhu Zhu, Hui Xu, Yaqiao Gao, Pei Wang, Daxin Gao. A novel TLR8 agonist induces immune responses and tumor regression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3264.
JAMA Psychiatry
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Shannon Sparenga, Nicole Balin, Miriam Cintron, Paul Ruich, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamczyk, Stephanie Alden, Jan Beckmeyer, Mary Clavey, Paula Coerver-Connolly, Roya Glitman, Laura Khatiblou, Donna King, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Lenette Gardner-Gullens, Fanny Brown, Paul Frank, Peter Kim, Rachell Lozano, Michaela Mark, Kathryn Muskovich, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Will English, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Joshua Bird, Karen Bucher, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Preeti Malani, Deanna Bellandi, Jim Periodical, Thomas Easley, Brian Shields, Monica Smith, Jeffery Bonistalli Manager, Kathy Russell, Mirna Monal, Stacey Mchugh, Thalia Moss, Mike Harvey, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, David Baum, Rebecca Haas, Christine Hearne, Irma Lara, Ron Marketing, Paul Gee, Matt Herron, Elizabeth Solaro, Geoffrey Flick Managers, Rick Bell, Lindsay Dawson, Michael Mcgraw, Sara Nagy, Romando Rossini, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sean O'donnell, Sue Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Scott Curl, Diane Darnell, Colleen Kelly, Chris Meyer, Jaye Mize, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Tiffany Jones, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Maria Nienhaus, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Dan Blazer, North Carolina, David Braff, La Jolla, Naomi California, Stephen Breslau, Washington Dager, Atlanta Druss, Susan Georgia, New Essock, New York, Ellen York, John Hardy, James Harris, Maryland Shitij Kapur, Kenneth Kendler, Virginia Ronald, C Kessler, Kathleen Merikangas, Maryland Samples O'malley, Michael Owen, Fmed Sci, Judith Rapoport, Maryland Charles, F Reynolds, Myrna Weissman, Naomi Wray, Charles Zorumski, St Louis, Roy Grinker Sr, Daniel Freedman, Janck Barchas, Joseph Coyle, Jennifer Urbano Blackford, Dost Öngür, Ira Phillips, Helena Chmura Kraemer, Howard Bauchner, Stephan Heckers
Journal: JAMA Psychiatry (2015)
mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109)
Authors: M. Geissler, U.M. Martens, R. Knorrenschield, J. Greeve, A. Florschuetz, A. Tannapfel, S. Wessendorf, T. Seufferlein, S. Kanzler, V. Heinemann, S. Held, A. Reinacher-Schick
Journal: Annals of Oncology (2017)
SURGICAL SURVIVAL
Authors: S. H. May
Journal: JAMA (1953)

<h3>To the Editor:—</h3> The editorial in the Oct. 24, 1953, issue ofThe Journal, "Surgical Survival of the Young and of the Aged," contains a passage that states that elderly patients are more susceptible to anoxia than young patients. This statement is open to debate. Experiments of German investigators (Ruff, S.: Grundriss der Luftfahrtmedizin, Leipzig, 1944, J. A. Barth, p. 94) in the medium of low pressure chambers, in combination with graduated exercise tests within them, showed that tolerance to oxygen want uniformly increases, that is, susceptibility to anoxia decreases with advancing age. As previously stated (May, S. H.: Air Travel and the Cardiac Patient,<i>Am. Heart J.</i><b>40</b>:363, 1950), this should not be too surprising. Variations in oxygen tension and acid-base equilibrium of the blood are chiefly controlled by the chemoreceptor fibers in the aortic and carotid bodies. It must be thought that the challenge to these nerve
"PSEUDO-PSEUDO-"
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Review: Statins prevent stroke and reduce mortality
Authors: Graeme J. Hankey
Journal: Annals of Internal Medicine (2008)

ACP Journal Club15 July 2008Review: Statins prevent stroke and reduce mortalityGraeme J. Hankey, MD, FRACP, FRCPGraeme J. Hankey, MD, FRACP, FRCPRoyal Perth Hospital,, Perth, Western Australia, Australia (G.J.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-149-2-200807150-02007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationO’Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121, 000 patients. Am J Med. 2008;121:24-33. https://pubmed.ncbi.nlm.nih.gov/18187070Clinical Impact RatingsGIM/FP/GP: Cardiology: Neurology: References1 Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781-90. [PMID: 17559928] Google Scholar2 Mihaylova B, Briggs A, Armitage J, et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20, 536 individuals. Lancet. 2005;365:1779-85. [PMID: 15910950] Google Scholar3 Ebrahim S, Sung J, Song YM, et al. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ. 2006;333:22. [PMID: 16757495] Google Scholar4 Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. In press. [PMID: 18077795] Google Scholar Author, Article, and Disclosure InformationAuthors: Graeme J. Hankey, MD, FRACP, FRCPAffiliations: Royal Perth Hospital,, Perth, Western Australia, Australia (G.J.H.)This article was published at Annals.org on 1 July 2008. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 July 2008Volume 149, Issue 2Page: JC1-7KeywordsCholesterolHemorrhagic strokeIschemic strokeLow density lipoproteinMedical risk factorsMortalityRelative riskStatinsStrokeToxicology ePublished: 15 July 2008 Issue Published: 15 July 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Depression predicts 12-month prognosis in elderly patients with acute myocardial infarction Issei Shiotani, Hiroshi Sato, Hideyuki Sato, Eiji Hishida, Kunihiro Kingjoe, Daisaku Nakatani, Noritake Hoki, Tsunehiko Kuzuya. Masatsugu Hori, Yozo Ohnishi. Osaka University Graduate School, department of Internal Medicine and Therapeutics, Suita, Japan, Osaka prefectural general hospital, Osaka, Japan
Journal: Journal of the American College of Cardiology (2001)
Attempted prevention of neonatal thyrotoxicosis.
Authors: I Ramsay
Journal: BMJ (1976)

thyroid, and increased lipofuscin deposition.Increasing use of mino- cycline could produce additional examples.Pigmentation of the thyroid need not cause functional upset.However, nuclear pyknosis indicates epithelial damage, and the studies of Benitz et al showed that minocycline has an antithyroid effect.Patients on long-term minocycline should have their thyroid function monitored.
The Evolution of the Diseases of Women.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal